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Introduction: The objective of this study was to identify and char-
acterize echinoderm microtubule-associated protein-like 4 anaplastic 
lymphoma kinase fusion (EML4-ALK+) cancers by variant-specific, 
quantitative reverse transcription polymerase chain reaction (RT-PCR) 
assays in a large cohort of North American non–small-cell lung  cancer 
(NSCLC) patients.
Methods: We developed a panel of single and multiplex RT-PCR 
assays suitable for rapid and accurate detection of the eight most 
common EML4-ALK+ variants and ALK gene expression in archival 
formalin-fixed, paraffin-embedded NSCLC specimens. EGFR and 
KRAS genotyping and thymidylate synthase RNA level by RT-PCR 
assays were available in a subset of patients.
Results: Between December 2009 and September 2012, 7344 NSCLC 
specimens were tested. An EML4-ALK+ transcript was detected in 
200 cases (2.7%), including 109 V1 (54.5%), 20 V2 (10.0%), 68 V3 
(34.0%), and three V5a (1.5%) variants. Median age was 54.5 years 
(range, 23–89), and 104 patients (52.0%) were women. The great 
majority (n=188, 94.0%) of EML4-ALK+ NSCLC tumors had adeno-
carcinoma histology. ALK expression level varied significantly among 
different EML4-ALK+ variants and individual tumors. Only one case 
each of concurrent EGFR or KRAS mutation was detected. The median 
thymidylate synthase RNA level from 85 EML4-ALK+ cancers was 
significantly lower compared with that of EML4-ALK-negative lung 
adenocarcinomas (2.02 versus 3.29, respectively, p<0.001).
Conclusions: This panel of variant-specific, quantitative RT-PCR 
assays detects common EML4-ALK+ variants as well as ALK gene 
expression level in archival formalin-fixed paraffin-embedded 
NSCLC specimens. These RT-PCR assays may be useful as an 
adjunct to the standard fluorescence in situ hybridization assay to bet-
ter understand biologic variability and response patterns to anaplastic 
lymphoma kinase inhibitors.
Key Words: Echinoderm microtubule-associated protein-like 4 ana-
plastic lymphoma kinase fusion variants, Formalin-fixed, Paraffin-
embedded, Non–small-cell lung cancer, Quantitative, Reverse 
transcription polymerase chain reaction.
(J Thorac Oncol. 2014;9: 18–25)
Originally discovered in lymphomas,1,2 the overexpres-sion of the anaplastic lymphoma kinase (ALK) gene by 
mutations, amplification, and translocations has since been 
identified as an oncogenic driver in several cancers includ-
ing inflammatory myofibroblastic tumors, neuroblastomas, 
inflammatory breast cancer, and non–small-cell lung can-
cer (NSCLC).3–7 The echinoderm microtubule-associated 
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protein-like 4 anaplastic lymphoma kinase (EML4-ALK) 
fusion oncogene represents one of the newest molecular tar-
gets in NSCLC. First described by Soda et al.4 in 2007, the 
fusion oncogene results from a small inversion within chromo-
some 2p, in which the N-terminal half (exons 1–20) of EML4 
gene is fused to the intracellular kinase domain (exons 20–29) 
of the ALK gene.8 EML4-ALK fusion (EML4-ALK+) prod-
ucts possess hyperactive tyrosine kinase activity and potent 
oncogenic activity both in vitro and in vivo.4,9 This activity 
can be effectively blocked by small-molecule tyrosine kinase 
inhibitors (TKIs) that target ALK.9,10 An increasing number 
of EML4-ALK+ variants have been reported in NSCLC.4,7,10–14 
In addition, several other rare 5′ fusion partners for ALK gene 
in NSCLC have also been described, such as tropomyosin-
receptor-kinase-fused gene (chromosome 3),15 kinesin fam-
ily member 5B (chromosome 10),16 and kinesin light chain 1 
(chromosome 14)17 as well as ALK–protein tyrosine phospha-
tase, nonreceptor Type 3 fusion oncogene.18
Crizotinib (PF-02341066; XALKORI, Pfizer, NY) is an 
oral small-molecule receptor TKI against ALK, hepatocyte 
growth factor receptor (c-Met), and ROS1.19,20 Early clinical 
experience demonstrated that treatment with crizotinib yields 
a response rate of 51% to 61% and a median progression-free 
survival of 8 to 10 months in patients with ALK+ advanced 
NSCLC,21–24 regardless of the number of prior treatment 
regimens. Survival benefit has also been suggested in retro-
spective analyses.25 Although the ALK fluorescence in situ 
hybridization (FISH) test was clinically validated in early-
phase crizotinib trials, alternative screening techniques,21 
most commonly immunohistochemistry (IHC) and reverse 
transcription polymerase chain reaction (RT-PCR), have been 
explored for detection of candidate patients for ALK inhibi-
tor therapy.25 We were among the first group of laboratories 
that developed quantitative RT-PCR assays that were opti-
mized for use of clinical samples, before the U.S. Food and 
Drug Administration (FDA) approved the Vysis ALK Break-
Apart FISH Probe Kit (Abbott Molecular Inc., Des Plaines, 
IL) for detection of ALK gene rearrangements.26 We report 
here the detection of EML4-ALK+ and ALK gene expression 
in archival North American NSCLC tumor specimens in the 
Response Genetics, Inc. (RGI) sample repository by a panel 
of variant-specific, quantitative RT-PCR assays and implica-
tions for clinical application.
MATERIALS AND METHODS
Tissue Procurement and 
Isolation of Nucleic Acids
Formalin-fixed, paraffin-embedded (FFPE) archival 
tumor specimens from patients with advanced NSCLC sent to 
the Clinical Laboratory Improvement Amendments (CLIA)–
certified RGI for genotyping and the expression of molecu-
lar biomarkers predictive of drug sensitivity were included in 
this study. Figure 1 summarizes the study subjects included 
in this report. A hematoxylin and eosin–stained section of all 
FFPE specimens from each NSCLC patient was evaluated by 
a board-certified pathologist (GZ) for diagnosis confirmation 
and tumor content. Tumor specimens were obtained from core 
or fine-needle aspiration, surgical resection, or cell blocks 
from body fluids on a case-by-case basis. Adjacent sections 
of the tumor were sectioned and stained with nuclear fast red 
(NFR) for visualization for gross microdissection. Tumor cells 
were microdissected by laser capture from 10-µm nuclear fast 
red–stained slides if present in less than 50% of a specimen. 
After isolation and lysis of the tumor cells, RNA and DNA 
were isolated separately from the specimen by RGI-patented 
methods, and the RNA was then reverse transcribed to cDNA 
for subsequent RT-PCR assays as previously described.26,27
RT-PCR Assays for EML4-ALK Fusion 
Genes and ALK Expression
Synthetic fragments representing the eight EML4-
ALK+ variants 1, 2, 3a, 3b, 4, 5a, 6, and 7 were generated 
Lung Adenocarcinomas
N=7344
EML4-ALK-Neg Cases
N=7144
EML4-ALK-Neg Cases 
with TS Data
N=1698
EML4-ALK-Pos Cases
N=200
EML4-ALK-Pos Cases 
with TS Data
N=85
EML4-ALK-Neg Cases 
without TS Data
N=5446
EML4-ALK-Pos Cases
with TS Data
N=115 FIGURE 1.  Summary of study subjects. NSCLC 
cases were grouped into EML4-ALK-Neg and 
EML4-ALK-Pos cases, then subdivided into 
patients who were positive or negative for TS 
expression. NSCLC, non–small-cell lung cancer; 
EML4-ALK, echinoderm microtubule-associated 
protein-like 4 anaplastic lymphoma kinase; TS, 
thymidylate synthase.
20 Copyright © 2013 by the International Association for the Study of Lung Cancer
Li et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
by recursive PCR technology.26 Figure 2 illustrates the primer 
locations and sequences designed by using the synthetic frag-
ments as templates to detect specific EML4-ALK+ gene frag-
ments with a maximum amplicon of 170 bases by RT-PCR. 
For each variant, a specific forward (5′) primer located in 
the corresponding EML4 region was used with a common 
reverse primer (3′), located in exon 20 of the ALK gene. For 
the RT-PCR assays, the most common variants 1 and 2 were 
run individually. Variants 3a and 3b, variants 4 and 7, and 
variants 5a and 6 were multiplexed, respectively. The multi-
plexed amplicons were separated by agarose gel electropho-
resis and the size of the amplicons was compared with the 
FIGURE 2.  Schema of RT-PCR primer locations and sequences for the expression of EML4-ALK+ variants. A, ALK gene structure 
with main domains marked: SP, signal peptide; MAM, meprin, A-5 protein, receptor protein tyrosine phosphatase mu; LDL, low-
density lipoprotein binding domain. The reverse RT-PCR primer for all variants is located in exon 20 as depicted. B, EML4 gene 
structure with main domains marked: CC, coiled coil domain; HELP, hydrophobic echinoderm microtubule-associated protein-
like protein; WD, WD-repeat domain. The approximate location of the forward RT-PCR primer for each variant is depicted. C, 
The resulting EML4-ALK fusion gene structure is shown. D, Sequences for EML4-ALK fusion transcript RT-PCR primers used. E, 
Representative PCR products of EML4-ALK fusion transcripts. The RT-PCR amplicons were separated by agarose gel electrophore-
sis and the size of specific amplicons was compared with the known molecular weight and synthetic positive controls. EML4-ALK 
variants 1, 2, 3a and 3b, and 5a and 6 are represented in gels a, b, c, and d, respectively. First lane: MS = marker standard (posi-
tive control); second lane: NTC = no template control; third lane: H-2228, an EML4-ALK variant 3a/3b-positive lung adeno-
carcinoma cell line; fourth and fifth lanes = patient samples run in duplicate. RT-PCR, reverse transcription polymerase chain 
reaction; EML4-ALK, echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase; TS, thymidylate synthase.
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known molecular weight and synthetic positive controls. 
The amplicons of any unexpected size and selected cases 
were confirmed by direct sequencing by using ABI 3730 
DNA Analyzer (Applied Biosystems Inc, Foster City, CA). 
ALK RNA level was detected by an RT-PCR assay by using 
a set of primers (3′-ALK-F, CCCTGCAAGTGGCTGTGA; 
3′ALK-R, GGCTTCCATGAGGAAATCCA; 3′-ALK-T, 
CGTCCTGTTCAGAGCACACTTCAGGC) amplifying a 3′ 
nonfusion fragment of the ALK gene in the tyrosine kinase 
domain at the junction of exons 21 and 22. Beta-actin was 
used as the reference gene for quality and quantity of cDNA.
RT-PCR Assays for Genotyping and 
Thymidylate Synthase Expression Level
The EGFR RGQ PCR Kit (QIAGEN, Valencia, CA) 
was used to detect 29 specific somatic mutations, insertions, 
and deletions in the epidermal growth factor receptor (EGFR) 
gene using real-time polymerase chain reaction (PCR) on 
the Rotor-Gene Q 5plex HRM instrument (QIAGEN).27 The 
EGFR RGQ PCR kit enables the detection of EGFR E19del, 
L858R, L861Q, T790M, G719S/A/C, S768I, and E20ins 
mutations against a background of wild-type genomic DNA. 
Kirsten rat sarcoma (KRAS) mutation analysis was performed 
with an RGI in-house mutation RT-PCR assay using specifi-
cally designed primers and probes to detect each of the fol-
lowing mutations: Gly12Ala (GGT>GCT) 522; Gly12Asp 
(GGT>GAT) 521; Gly12Arg (GGT>CGT) 518; Gly12Cys 
(GGT>TGT) 516; Gly12Ser (GGT>AGT) 517; Gly12Val 
(GGT>GTT) 520; Gly13Asp (GGC>GAC) 532. The expres-
sion level of thymidylate synthase (TS) gene expression was 
determined by an established RT-PCR assay by using spe-
cific primers and analyzed through an Excel template using 
the 2(-Delta Delta threshold cycle (Ct) method as previously 
described.26,27
Statistical Analysis
All statistical tests were performed using the SAS sta-
tistical program, version 9.3. Descriptive statistics were used 
to characterize patient’s clinical–pathological features. Gene 
expression levels of the ALK and TS genes were log-trans-
formed to render them normally distributed. Analysis of vari-
ance was used to test the difference in ALK RNA level across 
different EML4-ALK+ variants. The difference in TS RNA lev-
els by EML4-ALK+ status was compared using the Wilcoxon 
rank sum test as the data were not normally distributed. All 
tests were two-sided, with a significance level of 0.05.
RESULTS
Large-Scale Screening for EML4-ALK+ Variants
This current report combines the results of EML4-ALK 
RT-PCR analysis using both residual tumor nucleic acids from 
the RGI sample repository,28 and subsequent tumor specimens 
analyzed prospectively.28,29 Together, between December 2009 
and September 2012, 7344 NSCLC specimens in the RGI 
sample repository were tested for the presence of EML4-
ALK+ variants (Fig. 1).29 We found that 200 NSCLC cases 
(2.7%) harbored one of the EML4-ALK+ variants (Table 1). 
The median age of patients with EML4-ALK+ variants was 
54.5 (range, 23–89) years old. One hundred and four (52.0%) 
were women. The majority (94.0%) of EML4-ALK+ tumors 
were adenocarcinomas. However, EML4-ALK+ variants were 
also rarely detected in squamous cell carcinomas (n=4), ade-
nosquamous cell carcinomas (n=3), and large-cell carcinomas 
(n=1) (Table 1).
Of the 200 EML4-ALK+ NSCLC tumors, 109 cases 
(54.5%) were V1 variant, 20 cases (10.0%) were V2 variant, 
TABLE 1.  Detection of EML4-ALK+ Transcripts in NSCLC in 
RGI Sample Repository
Period of RGI database December 2009–September 2012
Total number of NSCLC cases 7344
No. of EML4-ALK+ cases 200
Prevalence of EML4-ALK+ cases 2.7%
Sex: female (%) 109 (52 %)
Median age, yrs (range) 54.5 (23–89)
Histology
  Adenocarcinoma 188 (94.0%)
  Large-cell 1 (0.5%)
  Squamous cell carcinoma 4 (2.0%)
  Adenosquamous cell carcinomas 3 (1.5%)
  Not specified 4 (2.0%)
NSCLC, non–small-cell lung cancer; EML4-ALK+, echinoderm microtubule-
associated protein-like 4 anaplastic lymphoma kinase fusion; RGI, Response Genetics, Inc.
V1
54.5%
V2
10.0%
V3
34.0%
V5a
1.5%
V1
V2
V3
V5a
FIGURE 3. EML4-ALK+ variants in NSCLC tumors (N=200). 
Distribution of various EML4-ALK fusion variant. EML4-ALK, 
echinoderm microtubule-associated protein-like 4 anaplastic 
lymphoma kinase; EGFR, epidermal growth factor receptor; 
SCC, squamous cell carcinoma; AD, adenocarcinoma; LC, 
large cell carcinoma; NOS, not otherwise specified.
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68 cases (34.0%) were V3 variant, and three cases (1.5%) were 
V5a variant (Figure 3, Table 2). In addition, by using V3 prim-
ers we identified two cases harboring an 18-base-pair inser-
tion between exon 6 of EML4 and exon 20 of ALK genes.14 
We further determined the expression of ALK RNA level by 
a separate quantitative RT-PCR, which spans the junction of 
exon 21 and 22 of the ALK tyrosine kinase domain (Fig. 2). 
ALK expression levels varied significantly between the com-
mon EML4-ALK+ variants (Fig. 4A). About 2.5% of EML4-
ALK-negative tumors had high ALK RNA expression level 
(Fig. 4B), which might because of the presence of other fusion 
partners or because of the high expression of full-length ALK 
transcript. Although no direct cross comparison with the ALK 
FISH assay is possible in this case series, in the recent New 
York State validation test, this panel of EML4-ALK RT-PCR 
assays had 93.3% concordance with ALK FISH assay done at 
an external CLIA-certified institution, with the sensitivity of 
83.3% (n=6) and specificity of 100% (n=23).
RT-PCR Assays for Genotyping and TS RNA 
Level in EML4-ALK+ NSCLC Tumors
Of the 200 EML4-ALK+ NSCLC cases, EGFR and 
KRAS genotype data were available from 189 (94.5%) and 
90 (45.0%) cases, respectively (Fig. 3A). All EML4-ALK+ 
NSCLC cases tested had wild-type EGFR and KRAS genes, 
except one 79-year-old man had lung adenocarcinoma har-
boring an EGFR exon 19 deletion concurrently with an 
EML4-ALK+ V1 variant and one 60-year-old man with lung 
adenocarcinoma harboring an KRAS Gly12Asp mutation con-
currently with an EML4-ALK+ V3 variant (Fig. 3). TS mRNA 
levels were available from 85 EML4-ALK+ lung adenocarci-
noma cases (Fig. 5), with low TS RNA expression defined as a 
level of less than 2.33, as previously described.30 ALK-negative 
lung adenocarcinomas served as an appropriate control group, 
based on our previous report.31 The median TS RNA level was 
significantly lower in EML4-ALK+ lung adenocarcinomas 
compared with that of EML4-ALK− lung adenocarcinomas 
(2.02 versus 3.29, respectively, p<0.001; Fig. 5).32
DISCUSSION
Two unmet needs in the clinical application of ALK 
TKIy agents are: (1) to establish a rapid and cost-effective 
diagnostic algorithm to identify this uncommon molecular 
subset of NSCLC; and (2) to understand molecular heteroge-
neity in responsiveness of ALK+ NSCLC tumors to optimize 
treatment strategies in the era of personalized cancer therapy. 
Several diagnostic techniques, including FISH, immuno-
histochemistry (IHC), and RT-PCR, have been explored for 
identifying candidate patients for ALK inhibitor therapy. 
Here we report development of a panel of quantitative mono-
plex and multiplex RT-PCR assays for the rapid detection of 
EML4-ALK+ variants and high ALK gene expression in a 
large (N=7344) cohort of archival FFPE NSCLC specimens 
in a commercial laboratory sample repository. It is worth 
emphasizing that our group was among the first to optimize 
RT-PCR assays suitable for clinical testing on archival tumor 
specimens in 2010,26 before the Vysis ALK Break-Apart FISH 
Probe Kit (Abbott Molecular Inc., Des Plaines, IL) for detect-
ing ALK gene rearrangements was approved by the U.S. FDA 
as a companion diagnostic of ALK inhibitor crizotinib. To our 
knowledge, this is the largest cohort of EML4-ALK+ cases in 
unselected NSCLC tumors reported to date.
Consistent with previous reports,4,10,13,21 we found that 
EML4-ALK+ variants are present in a small subset (2.7%) of 
North American NSCLC patients whose tumors were tested 
for molecular biomarkers (Table 1). Although the incidence 
of EML4-ALK+ variants in our series might be slightly lower 
than that reported using ALK FISH overall, or series enriched 
by adenocarcinoma histology only, and/or never smokers 
and former light smokers, it is within the expected range. Of 
200 EML4-ALK+ NSCLC tumors, V1 variant was the most 
common variant (54.5%) detected, followed by V3 (34.0%), 
V2 (10.0%), and V5a (1.5%; Fig. 3). Although the majority 
(n=188, 94.0%) of the EML4-ALK+ NSCLC tumors in our 
study had lung adenocarcinoma histology, EML4-ALK+ tran-
scripts were detected in other histologic types of NSCLC, 
including squamous cell carcinomas (n=4), adenosquamous 
cell carcinomas (n=3), and large-cell carcinoma (n=1).
Of interest, we detected one case each of concordant 
ALK+ and either EGFR or KRAS mutation, respectively. 
A similar phenomenon, that is, the simultaneous detection 
of both an ALK gene rearrangement and an EGFR or KRAS 
mutation, has been previously reported by several investiga-
tors.33–36 A recent report demonstrated simultaneous detection 
of an EML4-ALK+ variant and an EGFR exon 19 deletion in 
a lung cancer case of combined small-cell and lung adeno-
carcinoma components,37 suggesting that neither tumor type 
nor histology alone are absolute determinants for guiding 
cancer genetic testing. These additional mutations may serve 
as mechanisms of primary or acquired resistance of ALK+ 
NSCLC tumors to ALK TKI therapy,38,39 and represent drug 
TABLE 2.  Demographics and Genotypes of EML4-ALK+ NSCLC Tumors in this Study
 EML4-ALK Fusion Variants: (N=200) V1 V2 V3 V5
No. of cases (%): 109 (54.5%) 20 (10.0%) 68 (34.0%) 3 (1.5%)
Age, yr: median (range) 52.5 (23–79) 57.8 (36–77) 57.4 (33–89) 56.5 (50–73)
Gender: female (%) 60 (55.0%) 10 (50.0%) 32 (47.0%) 2 (66.7%)
Non-adenocarcinoma histology 2 SCC, 1 AS, 1 LC, 2 NOS 1 SCC 1 SCC, 2 AS, 1 NOS 1 NOS
EGFR mutation (N=189): 1 (E19del) 0 0 0
KRAS mutation (N=85): 0 0 1 (Gly12Asp) 0
SCC, squamous cell carcinoma; AS, adenosquamous; LC, large cell; NOS, not otherwise specified.
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targets for subsequent therapy. Importantly, EGFR mutant 
ALK+ tumors may respond to an EGFR TKI, similarly to 
those EGFR mutant ALK-negative tumors.36,38 Our results sup-
port the increasing use of multiplex genotyping and genomic 
profiling tests in individual NSCLC patients for selecting 
molecularly targeted therapy,40 an approach that needs to be 
proven cost effective because of the low prevalence of drug-
gable genetic anomalies and high test cost. Currently, both 
the National Comprehensive Cancer Network and American 
Society of Clinical Oncology guidelines recommend EGFR 
mutation and ALK+ testing on all NSCLCs that contain an 
adenocarcinoma component, regardless of histologic grade or 
dominant histologic subtype.41,42
Of particular interest, we found that ALK expression 
level varied significantly among different EML4-ALK+ vari-
ants (Fig. 4A) and individual tumors (Fig. 4B). A recent study 
suggests that different EML4-ALK variants as well as other 
ALK fusion genes exhibit differential sensitivity to ALK inhi-
bition, likely because of variability in overall fusion protein 
stability.43 The biological and clinical significance of variable 
expression of different EML4-ALK+ variants and the thresh-
old of ALK expression level for predicting response to an ALK 
FIGURE 5. TS RNA levels in EML4-
ALK+ and EML4-ALK-negative lung 
adenocarcinomas. A, TS RNA levels. 
Of 200 EML4-ALK+ cases, TS expres-
sion data were available for 85 cases 
with a median expression of 2.02. 
In the EML4-ALK-negative cases, TS 
expression data were available for 
1698 of 7144 cases, with a median 
expression of 3.29. B, EML4-ALK-pos 
lung adenocarcinomas. Overall TS 
expression in the 85 EML4-ALK-pos 
lung adenocarcinomas. C, EML4-ALK-
neg lung adenocarcinomas. Overall 
TS expression in the 1698 EML4-
ALK-neg lung adenocarcinomas. 
EML4-ALK, echinoderm microtubule-
associated protein-like 4 anaplastic 
lymphoma kinase; TS, thymidylate 
synthase.
FIGURE 4. ALK RNA levels in EML4-ALK+ variants (N=113). A, ALK RNA levels in different EML4-ALK fusion variants. RNA expres-
sion level for EML4-ALK variants divided by expression of β-actin control is shown for variant 1 (V1), variant 2 (V2), and vari-
ant 3 (V3). B, Variable intertumor ALK RNA level in NSCLC. High ALK expression was detected in 2.5% of EML4-ALK negative 
cases, shown in blue, when compared with EML4-ALK-positive expression levels. EML4-ALK, echinoderm microtubule-associated 
protein-like 4 anaplastic lymphoma kinase.
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inhibitor is unknown, but warrants further evaluation in pre-
clinical models and prospective clinical trials, respectively.
Although crizotinib offers a new standard of care for 
patients with ALK+ NSCLC tumors, only about 60% of 
patients exhibit Response Evaluation Criteria in Solid Tumors 
response and eventually all patients progress, with a median 
progression-free survival of about 8 to 10 months. As cytotoxic 
chemotherapy remains the mainstay of treatment for patients 
with advanced NSCLC, it is important to discern potential 
differential sensitivity patterns of ALK+ tumors to chemo-
therapy. Several reports have suggested that pemetrexed is 
particularly active in patients with ALK+ tumors,44–46 but this 
is controversial.47 To investigate this premise, we analyzed TS 
gene expression levels, a purported biomarker of pemetrexed 
sensitivity, in our series. We found that TS expression was sig-
nificantly lower in ALK+ tumors compared with ALK− lung 
adenocarcinoma controls, although the interpatient range of 
expression was wide (Fig. 5). This provides a potential molec-
ular mechanism for increased clinical benefit seen in ALK+ 
NSCLC patients treated with pemetrexed. These data remain 
hypothesis-generating and require prospective validation.
The use of RT-PCR assays on nucleic acids from archival 
FFPE tumor specimens has been standardized for genotyping 
and molecular profiling studies in CLIA-certified laboratory. 
RT-PCR assays allow maximal use of scant nucleic acids 
from limited archival tumor specimens or blood and other 
body fluids for molecular diagnostic tests.48 Lessons learned 
from molecular testing in chronic myeloid leukemia reveal 
that quantitative RT-PCR is a more sensitive test than FISH 
for monitoring residual disease during TKI treatment, detect-
ing 1-2-log reduction and ~5 log reduction, respectively.49 
In addition to high sensitivity and specificity, advantages of 
the multiplex RT-PCR assay include rapid turnaround time, 
less technical operating challenges, easy interpretation, low 
cost, and the RNA/cDNA from each tumor could be used for 
simultaneous assessment of other molecular biomarkers,50,51 
and most importantly, for DNA- or RNA-based genomic tests 
by next-generation sequencing technologies.
Nevertheless, our study has several limitations. First, 
patient samples were from an archival commercial sample 
repository, and the project was started before specific ALK 
FISH test received U.S. FDA approval as a companion diag-
nostic for crizotinib in 2011. No additional NSCLC specimens 
were available for the validation study of ALK FISH assay or 
IHC stain. Moreover, IHC test did not receive approval from the 
U.S. FDA. Nevertheless, our panel of RT-PCR assays passed 
the New York State validation test. Over the past 18 months, we 
performed both RT-PCR and FISH assays in approximately 900 
consecutive NSCLC tumors in our CLIA-certified laboratory. 
We found about 30 ALK+ cases, and the concordance between 
the two tests was 98% (RGI database on file). Furthermore, our 
quantitative RT-PCR assay targeting a conserved region of the 
ALK fusion partner allows assessment of the expression level of 
all ALK gene rearrangements regardless of their 5′ fusion part-
ners. The clinical utility of this quantitative RT-PCR assay could 
be evaluated in reference to ALK expression by FISH and IHC 
in prospective clinical studies. Second, only limited deidenti-
fied demographics (i.e., age and sex), were available. Smoking 
history and ethnicity information were not collected. Third, no 
clinical outcome data are available. Thus, a threshold of ALK 
expression level that predicts response to ALK inhibitors needs 
to be defined in future studies.
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